ACC 2019 Highlights: TAVR, Electrophysiology, Anti-thrombotic Therapies

A. Michael Lincoff, MD, Director of the Cleveland Clinic Coordinating Center for Clinical Research (C5Research), reviews the results from clinical trials presented at the 2019 American College of Cardiology Conference focusing on three major practice areas: 1) the use of transcatheter aortic valves (TAVR) in low risk patients (PARTNER 3, Evolut Low); 2) electrophysiology studies (Apple Heart, WRAP-IT) ; and 3) anti-thrombotic therapies in patients with atrial fibrillation, acute coronary syndrome or percutaneous intervention (AUGUSTUS, GLASSY). Dr. Lincoff summarizes the studies’ design and results, and provides insight into the potential impact on future care of patients based on these outcomes.